{"gene":"PDE4D","run_date":"2026-06-10T05:19:53","timeline":{"discoveries":[{"year":2009,"finding":"Co-crystal structures of PDE4D with inhibitors reveal that the regulatory domain (UCR2/CR3) closes across the active site, establishing the structural basis of allosteric regulation. Mutagenesis and kinetic studies confirmed that small-molecule allosteric modulators binding this closed conformation partially inhibit enzymatic activity (Imax ~80-90%) without fully blocking cAMP hydrolysis.","method":"X-ray co-crystallography (7 structures), site-directed mutagenesis, enzyme kinetics, cellular cAMP assays, in vivo emesis models","journal":"Nature biotechnology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple crystal structures with mutagenesis and kinetic validation in one rigorous study","pmids":["20037581"],"is_preprint":false},{"year":2000,"finding":"ERK2 phosphorylates PDE4D3 at Ser579 using FQF and KIM docking sites flanking the target residue; mutation of either docking site prevents ERK2 co-immunoprecipitation with PDE4D3, ablates EGF-mediated inhibition of PDE4D3 in transfected cells, and attenuates in vitro phosphorylation. The long-isoform UCR1/UCR2 regulatory module amplifies the inhibitory effect of ERK2 phosphorylation on the catalytic unit, whereas in the short isoform PDE4D1 (containing only UCR2), ERK2 phosphorylation activates the enzyme. Thus PDE4D encodes isoenzymes that are either inhibited or activated by ERK2.","method":"Site-directed mutagenesis of docking sites, co-immunoprecipitation, in vitro ERK2 kinase assay, transfected COS cell cAMP assay, truncation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — in vitro phosphorylation assay with mutagenesis, reciprocal Co-IP, cellular functional readout in one study","pmids":["10828059"],"is_preprint":false},{"year":1997,"finding":"The N-terminal unique regions of PDE4D3, PDE4D4, and PDE4D5 (derived from alternatively spliced exons) determine their subcellular localization: PDE4D1 and PDE4D2 are cytosolic only, while PDE4D3/4/5 partition between cytosolic and particulate fractions. Particulate forms of PDE4D3 and PDE4D5 show 2-7-fold higher IC50 for rolipram than their cytosolic counterparts.","method":"Transient expression in COS-7 cells, subcellular fractionation, immunoblotting of human cell lines and rat brain, rolipram IC50 determination","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — fractionation with functional inhibitor-sensitivity readout, replicated across five isoforms and native tissues","pmids":["9371713"],"is_preprint":false},{"year":1998,"finding":"PDE4D splice variants are targeted to discrete subcellular compartments in thyroid FRTL-5 cells: PDE4D3 is recovered in both soluble and particulate fractions and is solubilized by nonionic detergent, whereas PDE4D4 requires ionic detergent, indicating different anchoring mechanisms. TSH stimulation causes PKA-dependent electrophoretic mobility shift (phosphorylation) and activation of PDE4D3, and long-term TSH induces PDE4D2 expression in the soluble fraction. Immunofluorescence localizes PDE4D signal to plasma-membrane-adjacent cytoskeletal structures and a perinuclear region.","method":"Subcellular fractionation, differential detergent extraction, immunoblotting, immunofluorescence microscopy, TSH/cAMP stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (fractionation, detergent extraction, immunofluorescence) with hormone-regulated functional consequence","pmids":["9677395"],"is_preprint":false},{"year":1999,"finding":"PKA phosphorylates and activates PDE4D3 and PDE4D5 in vascular smooth muscle cells (VSMCs) in response to elevated cAMP. PKC-Raf-MEK-ERK activation also phosphorylates and activates PDE4D3 in VSMCs. Simultaneous activation of both PKA and PKC-Raf-MEK-ERK causes coordinated activation of PDE4D3 and translocation of particulate PDE4D3 to the cytosolic fraction.","method":"Pharmacological inhibitors (PKA, MEK), biochemical fractionation, in-cell phosphorylation assays in VSMCs","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two orthogonal activation pathways demonstrated with pharmacological + biochemical approaches, single lab","pmids":["10187850"],"is_preprint":false},{"year":2000,"finding":"PKA-dependent elevation of cAMP induces expression of PDE4D1 and PDE4D2 in VSMCs (feedback induction). Simultaneous activation of PKC-Raf-MEK-ERK blunts this cAMP-mediated induction of PDE4D through a mechanism involving decreased PDE4D mRNA stability, thereby attenuating cAMP desensitization.","method":"mRNA stability assays, pharmacological inhibitors (PKA, MEK, PKC), quantitative RT-PCR, immunoblotting in VSMCs","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mRNA stability mechanistic follow-up with pharmacological tools, single lab","pmids":["10851231"],"is_preprint":false},{"year":2003,"finding":"Crystal structures of the PDE4D2 catalytic domain complexed with (R)- or (R,S)-rolipram reveal that inhibitor selectivity is determined by the chemical nature of active-site residues and subtle conformational changes of the binding pocket; Gln369 conformation plays a key role in inhibitor recognition.","method":"X-ray crystallography of PDE4D2 catalytic domain–rolipram complexes, structural comparison with PDE5/PDE7","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with mechanistic interpretation of selectivity determinants","pmids":["12842049"],"is_preprint":false},{"year":1999,"finding":"Genetic inactivation of PDE4D in mice (PDE4D−/−) reduces total PDE4 activity and causes impaired ovulation and diminished gonadotropin sensitivity of granulosa cells, delayed growth, and reduced viability, demonstrating that PDE4D-mediated cAMP hydrolysis is required for normal gonadotropin signaling, growth, and fertility.","method":"Gene knockout mouse model, immunoblotting, PDE4 activity assay, ovulation and fertility phenotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with defined cellular phenotype (granulosa cell gonadotropin sensitivity) and biochemical confirmation of enzyme loss","pmids":["10518565"],"is_preprint":false},{"year":2000,"finding":"PDE4D−/− mouse airways are refractory to muscarinic cholinergic stimulation; muscarinic receptor-mediated decrease of cAMP is absent, and antigen-induced airway hyperreactivity is abolished despite normal inflammatory infiltration. The loss of response is airway-specific (not observed in heart), establishing PDE4D as essential for cAMP homeostasis and cholinergic signaling in airway.","method":"PDE4D−/− mouse model, airway resistance measurements, cAMP accumulation assays, antigen challenge model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with tissue-specific functional readout and biochemical cAMP measurement","pmids":["10841571"],"is_preprint":false},{"year":2003,"finding":"PDE4D−/− tracheas show 60% reduction in maximal cholinergic-evoked tension and five-fold decreased sensitivity to muscarinic agonists, with preserved responses to KCl and arginine vasopressin, identifying a specific role for PDE4D in muscarinic smooth muscle contraction. Elevated cAMP in PDE4D−/− airway leads to increased prostanoid (PGE2) accumulation; blockade of prostanoid synthesis restores muscarinic responses in vitro and in vivo.","method":"Isolated trachea contractility assays (PDE4D−/− vs WT), cAMP accumulation, prostanoid inhibition rescue experiments, in vivo airway measurements","journal":"FASEB journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with pharmacological rescue establishing mechanistic pathway, multiple readouts","pmids":["14519662"],"is_preprint":false},{"year":2008,"finding":"Ablation of PDE4D (but not PDE4A or PDE4B) in mouse embryonic fibroblasts markedly enhances beta2-adrenergic receptor (beta2AR)-induced PDE activation, prolongs cAMP accumulation and CREB phosphorylation, and delays return to basal cAMP levels. This effect is largely due to loss of a PKA-mediated negative feedback loop (PKA activates PDE4D to terminate the cAMP signal). PDE4D ablation also alters beta2AR desensitization kinetics and the receptor's interaction with Gαi.","method":"PDE4D/4A/4B knockout MEFs, cAMP accumulation assays, CREB phosphorylation, PKA inhibitors (H89/PKI), beta2AR desensitization and Gαi co-immunoprecipitation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform-selective KO MEFs with multiple orthogonal biochemical readouts establishing negative feedback mechanism","pmids":["18508768"],"is_preprint":false},{"year":2011,"finding":"PDE4D ablation in mouse embryonic fibroblasts enhances agonist-induced cAMP in the bulk cytosol and at the plasma membrane, whereas PDE4B ablation specifically elevates cAMP in a near-membrane pool without affecting bulk cytosol cAMP. PDE4D (but not PDE4B) ablation significantly prolongs CREB-mediated transcription. These results establish that PDE4D and PDE4B function in distinct subcellular cAMP compartments.","method":"PDE4B and PDE4D knockout MEFs, FRET-based cAMP sensors (cytosol and near-membrane), CREB-reporter assays, isoproterenol stimulation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with spatially resolved FRET cAMP measurements and transcriptional readout, multiple compartments tested","pmids":["21288894"],"is_preprint":false},{"year":2010,"finding":"PDE4D enzymes form a complex with EPAC1 at vascular endothelial cadherin (VE-Cad)-based intercellular junctions in human arterial endothelial cells. Protein–protein interactions between EPAC1 and PDE4D are required for their integration into VE-Cad complexes. Disruption of this interaction with a cell-permeable EPAC1 peptide antagonizes EPAC1–PDE4D binding and directly alters vascular permeability.","method":"Co-immunoprecipitation, biochemical fractionation, peptide competition assay, VE-cadherin complex isolation, permeability assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP with functional peptide-disruption readout establishing a defined signaling complex","pmids":["20732872"],"is_preprint":false},{"year":2016,"finding":"On fibronectin matrix, integrin α5 directly binds PDE4D5 and recruits PP2A (via B55α regulatory subunit) to dephosphorylate PDE4D5 at the inhibitory site Ser651, thereby activating the phosphodiesterase, suppressing cAMP, and promoting endothelial inflammatory signaling. In vivo knockdown of PDE4D5 inhibits inflammation at atherosclerosis-prone arterial sites.","method":"Integrin α5/α2 chimera knock-in mice, siRNA knockdown, Co-IP, phospho-specific antibodies (Ser651), cAMP measurement, in vivo endothelial inflammation assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — integrin chimera knock-in with biochemical mechanism (PP2A dephosphorylation site identified), in vivo validation","pmids":["27595237"],"is_preprint":false},{"year":2019,"finding":"The PP2A regulatory subunit B55α recruits PP2A to PDE4D5, directly dephosphorylating PDE4D5 at Ser651 (activating it) at focal adhesions. This PDE4D5-B55α-PP2A complex also dephosphorylates and activates YAP. Mutation of the integrin α5 binding site in PDE4D5 reduces endothelial inflammatory activation and atherosclerotic plaque size in a hyperlipidemic mouse model.","method":"Proteomics (mass spectrometry identification of B55α), Co-IP, in vitro phosphatase assay, PDE4D5 integrin-binding site knock-in mouse, atherosclerosis plaque quantification","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — proteomics-identified binding partner confirmed by Co-IP and in vitro phosphatase assay, in vivo knock-in model with disease readout","pmids":["31408443"],"is_preprint":false},{"year":2015,"finding":"CaMKII phosphorylates and activates PDE4D in cardiomyocytes in response to beta-adrenergic receptor stimulation, establishing a negative feedback loop that constrains basal and beta-AR-stimulated cAMP levels. This CaMKII→PDE4D axis integrates cAMP/PKA and Ca2+/CaMKII signaling pathways.","method":"CaMKII inhibitor pharmacology, PDE4D activity assays, cAMP measurements in cardiomyocytes, CaMKII activation/inhibition experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cellular kinase assay and cAMP measurements, single lab with pharmacological approach","pmids":["25646485"],"is_preprint":false},{"year":2014,"finding":"Phosphorylated HSP20 forms a complex with PDE4D in cardiomyocytes; peptide disruption of the HSP20–PDE4D interaction in human iPSC-derived cardiomyocytes attenuates action potential prolongation, and in a mouse pressure-overload model protects against adverse cardiac remodeling (improved contractility, reduced hypertrophy and fibrosis).","method":"Peptide disruption, human iPSC-cardiomyocytes electrophysiology, mouse pressure-overload hypertrophy model, cardiac histology and contractility","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — peptide disruption with defined complex and in vivo cardiac phenotype, single lab","pmids":["25426411"],"is_preprint":false},{"year":2017,"finding":"PDE4D5 isoform interacts with focal adhesion kinase (FAK) through the scaffolding protein RACK1 in BRAF-mutated melanoma cells; inhibition of PDE4D enzymatic activity or disruption of the PDE4D–FAK interaction reduces melanoma cell invasion in vitro.","method":"Co-immunoprecipitation (PDE4D5–RACK1–FAK), PDE4 pharmacological inhibitors, invasion assays, patient tissue detection by proximity ligation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — Co-IP establishing ternary complex with functional invasion readout, single lab","pmids":["28092671"],"is_preprint":false},{"year":2003,"finding":"PDE4D6 (supershort) and PDE4D7 (long) isoforms hydrolyze cAMP with high affinity and are inhibited by rolipram. PDE4D7 activity is elevated by PKA-dependent phosphorylation at the conserved UCR1 site, whereas PDE4D6 (lacking UCR1) is not activated by PKA.","method":"Baculovirus expression of recombinant PDE4D6/7, enzyme kinetics, PKA phosphorylation assay","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro enzyme assay with recombinant protein, single lab","pmids":["12834813"],"is_preprint":false},{"year":2007,"finding":"In mouse embryonic fibroblasts, short PDE4D1 isoforms localize to the nucleus via a nuclear localization signal in the unique N-terminal region, while supershort isoforms (PDE4D2, PDE4D6, PDE4D10) are restricted to the cytoplasm. Deletion of the N-terminus of PDE4D1 abolishes nuclear targeting.","method":"Subcellular fractionation, deletion mutagenesis, immunofluorescence microscopy","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — localization by fractionation and immunofluorescence with deletion mutant validation, single lab","pmids":["18006274"],"is_preprint":false},{"year":2009,"finding":"PDE4D controls GLP-1 release in GLUTag cells: rolipram enhances GLP-1 release in vivo (rats) and in vitro. Stable overexpression of catalytically-inactive D556A-PDE4D5 mutant elevates cAMP and increases basal and glucose-induced GLP-1 release; PKA inhibitor H89 partially blocks this increase, establishing that PDE4D4/5 regulates GLP-1 secretion via cAMP/PKA.","method":"PDE4 inhibitor (rolipram) in vivo and in vitro, stable overexpression of catalytically inactive PDE4D5 mutant, PKA inhibitor H89, GLP-1 ELISA","journal":"British journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative mutant overexpression with pharmacological rescue, single lab","pmids":["19371330"],"is_preprint":false},{"year":2009,"finding":"Transposon insertional mutagenesis in mouse prostate identified PDE4D as a proliferation-promoting factor; knockdown of PDE4D reduced growth and migration of human prostate cancer cells in vitro and reduced tumor xenograft growth in vivo.","method":"Sleeping Beauty transposon somatic mutagenesis screen, siRNA knockdown, in vitro proliferation/migration assays, xenograft tumor growth assay","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional KD with in vitro and in vivo growth readouts, single lab","pmids":["19401450"],"is_preprint":false},{"year":2014,"finding":"Acrodysostosis-associated PDE4D missense mutations (Gly673Asp and Ile678Thr) reduce catalytic activity in vitro; ectopic expression in HEK293 cells confirms reduced PDE4D activity by elevated cAMP. However, patient-derived cells paradoxically show low cAMP due to compensatory upregulation of PDE4A and PDE4B. PDE4D-knockout rats have shorter metacarpals and phalanges consistent with acrodysostosis.","method":"3D structural modeling, in vitro cAMP accumulation assay in HEK293 cells, patient-derived cell cAMP measurement, immunoblotting, PDE4D-KO rat radiographic phenotyping","journal":"Cellular signalling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ectopic expression functional assay plus KO rat phenotyping, multiple methods but single lab","pmids":["25064455"],"is_preprint":false},{"year":2012,"finding":"Heterozygous de novo missense mutations in PDE4D cause acrodysostosis (skeletal dysplasia, brachydactyly, nasal hypoplasia, intellectual disability) without hormone resistance, establishing that PDE4D loss-of-function disrupts cAMP homeostasis in bone and CNS. Functional assay confirmed by zebrafish: overexpression of mutated PDE4D mRNA and morpholino-based pde4d knockdown produce mirror skeletal phenotypes, validating the pathogenicity of point mutations.","method":"Exome sequencing, Sanger sequencing, zebrafish overexpression and morpholino knockdown, array CGH","journal":"Journal of medical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — zebrafish functional assay with both gain- and loss-of-function, confirmed by multiple human genetic studies","pmids":["24203977","22464252","22464250"],"is_preprint":false},{"year":2021,"finding":"Hepatic overexpression of PDE4D in mice induces NAFLD and hypertension via activation of fatty acid translocase CD36 signaling, leading to hepatocyte TGF-β1 production and vascular TGF-β1 signaling. siRNA silencing of TGF-β1 in hepatocytes normalizes the hypertension caused by PDE4D overexpression, placing PDE4D upstream of CD36–TGF-β1 in a liver-to-vessel axis.","method":"Hepatic PDE4D overexpression (adenovirus), liver-targeted TGF-β1 siRNA nanoparticles, hepatic steatosis histology, blood pressure measurement, CD36 signaling assays","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function overexpression with pathway-specific rescue (TGF-β1 siRNA), single lab","pmids":["34826603"],"is_preprint":false},{"year":2022,"finding":"PDE4D physically binds YAP in hepatocellular carcinoma cells; PDE4D overexpression increases YAP dephosphorylation and transcriptional activity to promote HCC growth. Roflumilast-mediated PDE4D inhibition activates cAMP-PKA, causing PKA-dependent YAP phosphorylation at Ser127 and YAP degradation. YAP-S127A mutant reverses roflumilast-mediated suppression, confirming PDE4D acts via PKA→YAP-S127.","method":"Co-immunoprecipitation (PDE4D–YAP), overexpression and knockdown, phospho-YAP(S127) immunoblotting, YAP-S127A rescue, roflumilast treatment, in vivo xenograft","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP establishing interaction, mutant rescue pinpointing mechanistic site, in vivo confirmation; single lab","pmids":["35597479"],"is_preprint":false},{"year":2023,"finding":"In pancreatic β cells, endoplasmic reticulum stress activates the PERK-ATF4 pathway, which transcriptionally induces PDE4D expression, reducing cAMP signaling and impairing incretin-stimulated insulin secretion. Pharmacological inhibition of ATF4 reduces PDE4D expression and restores β-cell function in db/db mice; PDE4D inhibition similarly rescues β-cell function in ATF4-transgenic and db/db mice.","method":"ATF4 transgenic mice, db/db mice, ATF4 pathway inhibitor, PDE4 inhibitor, cAMP measurement, glucose tolerance and insulin secretion assays, nuclear localization studies","journal":"American journal of physiology. Endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ATF4 transgenic plus pharmacological rescue in two mouse models establishing transcriptional regulation, single lab","pmids":["37729023"],"is_preprint":false},{"year":2025,"finding":"PDE4D is upregulated in failing hearts via isoproterenol-stimulated cAMP-PKA signaling. PDE4D overexpression suppresses CREB-SIRT1 signaling and PINK1/Parkin-mediated mitophagy, causing oxidative stress and cardiomyocyte hypertrophy; PDE4D knockdown or roflumilast reverses these effects. Cardiac-specific PDE4D haploinsufficiency protects against TAC-induced cardiac hypertrophy and heart failure in vivo; PDE4D overexpression abolishes this protection.","method":"Global and cardiac-specific PDE4D heterozygous KO mice, AAV9-PDE4D overexpression, TAC and isoproterenol mouse models, mitophagy assays (PINK1/Parkin), CREB-SIRT1 pathway immunoblotting, roflumilast treatment","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO plus overexpression with mechanistic pathway readout (CREB-SIRT1-mitophagy), single lab","pmids":["40015131"],"is_preprint":false},{"year":2015,"finding":"Arctigenin binds PDK1 (identified by chemical proteomics capture) and inhibits PDK1 kinase activity, leading to reduced Akt-mediated phosphorylation of PDE4D in human bronchial smooth muscle cells, thereby attenuating PDE4D activity and increasing cAMP accumulation. This PDK1/Akt/PDE4D axis was identified as a novel mechanism controlling airway smooth muscle relaxation.","method":"Chemical proteomics (drug-protein capture), molecular dynamics simulation, in vitro PDK1 kinase assay, PDE4D phosphorylation Western blot, cAMP measurement, tracheal smooth muscle contractility assay","journal":"Allergy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chemical proteomics identification with kinase assay and functional smooth muscle readout, single lab","pmids":["26335809"],"is_preprint":false},{"year":2018,"finding":"PDE4D overexpression in tamoxifen-resistant ER+ breast cancer cells suppresses cAMP/ER-stress/p38-JNK signaling and apoptosis. Inhibition of PDE4D (siRNA or pharmacological inhibitors) restores tamoxifen sensitivity by reactivating cAMP-mediated unfolded protein response/ER stress pathway and p38/JNK-dependent apoptosis.","method":"siRNA knockdown, pharmacological inhibitors (dipyridamole, GEBR-7b), cAMP measurement, UPR/p38/JNK pathway immunoblotting, apoptosis assays, in vivo xenograft tumor growth","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA and pharmacological inhibition with defined downstream pathway (cAMP→UPR→p38/JNK), in vivo confirmation; single lab","pmids":["29386221"],"is_preprint":false},{"year":2011,"finding":"PDE4D expression and activity are approximately 2-fold elevated in asthmatic airway smooth muscle cells, accounting for reduced beta2-agonist-induced cAMP accumulation; specific PDE4 inhibition normalizes cAMP production and reduces asthmatic ASM proliferation but not non-asthmatic ASM proliferation.","method":"Primary cultured ASM from asthmatic vs. non-asthmatic subjects, cAMP accumulation assay with/without PDE inhibitors, PDE4D protein quantification, proliferation assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — primary human cells with pharmacological rescue and functional proliferation readout, moderate sample size; single lab","pmids":["21611147"],"is_preprint":false},{"year":2020,"finding":"PDE4D protein localizes to dendrites associated with microtubules, mitochondria, and smooth endoplasmic reticulum, with postsynaptic labeling in dendritic spines near glutamatergic synapses and in perisynaptic astroglial leaflets in macaque dlPFC layer III pyramidal cell circuits, as determined by immunoelectron microscopy.","method":"Laser-capture microdissection transcriptomics, high-resolution immunoelectron microscopy in rhesus macaque dlPFC","journal":"Frontiers in neuroanatomy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ultrastructural localization by immunoelectron microscopy with transcriptomic support, but no direct functional consequence established in same study","pmids":["33328902"],"is_preprint":false},{"year":2014,"finding":"A co-crystal structure of PDE4B (catalytic domain) with triazine inhibitors shows the compounds interact with both the catalytic pocket and the C-terminal regulatory helix (CR3), locking the enzyme in an inactive 'closed' conformation; structure-activity relationships define CR3 contacts as the basis for PDE4B vs. PDE4D subtype selectivity.","method":"X-ray co-crystallography of PDE4B–triazine complex, structure-activity relationship analysis of selective inhibitors","journal":"Bioorganic & medicinal chemistry letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — crystal structure with SAR but selectivity mechanism for PDE4D inferred from PDE4B structure; direct PDE4D structure not determined","pmids":["24998378"],"is_preprint":false},{"year":2023,"finding":"In the PDE4D/cAMP/IL-23 axis in lung adenocarcinoma, PDE4D activity in tumor cells suppresses cAMP, reducing IL-23 production; PDE4D inhibition elevates cAMP and IL-23, which activates CTL NF-κB signaling to induce an IL-9 autocrine loop, enhancing CTL effector function and immunotherapy efficacy.","method":"Co-culture system (LUAD cells + tumor-specific CD8+ T cells), fluorescent multiplex IHC, transcriptome sequencing, functional validation with PDE4D manipulation and IL-23/IL-9/NF-κB pathway assays, in vivo mouse xenograft","journal":"Cancer letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multi-step pathway defined by functional assays in co-culture and in vivo; single lab","pmids":["37196909"],"is_preprint":false}],"current_model":"PDE4D is a cAMP-specific phosphodiesterase whose multiple splice variants (PDE4D1–9) are differentially targeted to distinct subcellular compartments via their unique N-terminal regions; catalytic activity is subject to complex post-translational regulation including PKA-mediated activation (providing negative feedback on cAMP signals), ERK2 phosphorylation that either inhibits (long isoforms via UCR1/UCR2) or activates (short isoforms via UCR2 alone) the enzyme, CaMKII-mediated activation, and integrin α5-recruited PP2A-B55α-mediated dephosphorylation of the inhibitory Ser651 site in PDE4D5; structurally, allosteric modulators exploit a regulatory domain that closes over the active site; in tissues PDE4D functions as the dominant terminator of beta2AR-stimulated cAMP in fibroblasts and heart, controls muscarinic cholinergic airway contraction, governs GLP-1 secretion and beta-cell function, mediates antidepressant and pro-cognitive effects of cAMP elevation, and promotes inflammation in atherosclerotic endothelium by suppressing cAMP downstream of fibronectin/integrin α5; loss-of-function mutations cause acrodysostosis by impairing cAMP-PKA signaling in bone, while gain-of-function or overexpression drives pathological remodeling in heart, liver, and cancer."},"narrative":{"mechanistic_narrative":"PDE4D is a cAMP-specific phosphodiesterase that serves as a dominant terminator of cAMP signaling across diverse tissues, with its multiple alternatively spliced variants (PDE4D1–7) differentially compartmentalized through unique N-terminal regions that confer cytosolic, particulate, or nuclear targeting [PMID:9371713, PMID:18006274]. Catalytic output is governed allosterically by a regulatory domain (UCR2/CR3) that closes over the active site, the conformation small-molecule modulators exploit to achieve partial inhibition [PMID:20037581]. The enzyme is integrated into multiple feedback and signaling networks: PKA phosphorylates and activates long PDE4D isoforms to terminate cAMP signals [PMID:9677395, PMID:18508768], ERK2 phosphorylation at Ser579 inhibits long isoforms (via UCR1/UCR2) but activates short isoforms bearing UCR2 alone [PMID:10828059], and CaMKII activates PDE4D in cardiomyocytes to constrain beta-adrenergic cAMP [PMID:25646485]. Conversely, integrin α5 binds PDE4D5 on fibronectin matrix and recruits PP2A via its B55α subunit to dephosphorylate the inhibitory Ser651 site, activating the enzyme, suppressing cAMP, and driving endothelial inflammation in atherosclerosis [PMID:27595237, PMID:31408443]. Through these compartmentalized circuits PDE4D controls beta2-adrenergic cAMP and CREB-dependent transcription in fibroblasts [PMID:18508768, PMID:21288894], muscarinic cholinergic airway contraction [PMID:10841571, PMID:14519662], and GLP-1 secretion and beta-cell function [PMID:19371330, PMID:37729023]. Loss-of-function missense mutations in PDE4D cause acrodysostosis, a skeletal dysplasia with brachydactyly and intellectual disability arising from disrupted cAMP-PKA signaling in bone and CNS [PMID:24203977, PMID:22464252, PMID:22464250, PMID:25064455], whereas elevated PDE4D drives pathological remodeling in heart, liver, and cancer, in part through PKA-dependent control of YAP phosphorylation and degradation [PMID:35597479, PMID:40015131].","teleology":[{"year":1997,"claim":"Established that PDE4D's multiple splice variants are not redundant but are addressed to distinct subcellular compartments by their unique N-termini, explaining how one gene tunes cAMP in different locations.","evidence":"Transient expression in COS-7 cells with subcellular fractionation and rolipram IC50 determination across five isoforms","pmids":["9371713"],"confidence":"High","gaps":["Did not define the molecular anchors binding each particulate isoform","Functional consequence of compartmentalization for cAMP gradients not measured"]},{"year":1998,"claim":"Showed that isoform targeting involves distinct anchoring mechanisms and that hormone-driven PKA phosphorylation activates PDE4D3, linking localization to regulated catalytic control.","evidence":"Subcellular fractionation, differential detergent extraction, immunofluorescence and TSH stimulation in FRTL-5 thyroid cells","pmids":["9677395"],"confidence":"High","gaps":["Identity of the ionic-detergent-resistant anchor for PDE4D4 not determined","PKA phosphosites not mapped in this study"]},{"year":2000,"claim":"Resolved how a single gene produces both ERK2-inhibited and ERK2-activated isoenzymes by mapping ERK2 docking sites and the role of the UCR1/UCR2 module, establishing isoform-dependent kinase regulation.","evidence":"Docking-site mutagenesis, reciprocal Co-IP, in vitro ERK2 kinase assay and cellular cAMP readouts in COS cells","pmids":["10828059"],"confidence":"High","gaps":["Physiological contexts where ERK2 inhibition versus activation dominates not defined","Crosstalk with PKA phosphorylation on the same isoform not resolved"]},{"year":1999,"claim":"Genetic ablation demonstrated PDE4D is required in vivo for gonadotropin signaling, growth, and fertility, moving the gene from a biochemical entity to an essential physiological cAMP regulator.","evidence":"PDE4D-/- knockout mouse with PDE4 activity assays and ovulation/fertility phenotyping","pmids":["10518565"],"confidence":"High","gaps":["Which isoforms mediate the granulosa cell phenotype not dissected","Cell-autonomous versus systemic contributions not separated"]},{"year":2003,"claim":"Defined PDE4D as essential for muscarinic cholinergic airway contraction and traced the knockout phenotype to elevated cAMP driving prostanoid accumulation, providing a mechanistic pathway for airway tone.","evidence":"PDE4D-/- trachea contractility, cAMP and prostanoid measurements with prostanoid-synthesis-blockade rescue, in vivo airway assays","pmids":["14519662","10841571"],"confidence":"High","gaps":["Specific cell type generating PGE2 not pinpointed","Isoform responsible for airway smooth muscle cAMP control not identified"]},{"year":2003,"claim":"Crystal structures of the catalytic domain with rolipram explained inhibitor selectivity at the residue level, including a key role for Gln369 conformation, informing selective inhibitor design.","evidence":"X-ray crystallography of PDE4D2 catalytic domain–rolipram complexes with comparison to PDE5/PDE7","pmids":["12834813","12842049"],"confidence":"High","gaps":["Catalytic domain alone does not capture regulatory-domain allostery","Isoform-specific kinetic differences not structurally explained"]},{"year":2009,"claim":"Co-crystal structures revealed the regulatory UCR2/CR3 domain closes over the active site, establishing the structural basis of allosteric, partial inhibition exploitable for safer therapeutics.","evidence":"Seven X-ray co-crystal structures with mutagenesis, enzyme kinetics, cellular cAMP assays and in vivo emesis models","pmids":["20037581"],"confidence":"High","gaps":["Dynamics of the open/closed equilibrium in full-length enzyme not captured","How post-translational modifications shift this equilibrium not resolved"]},{"year":2011,"claim":"Isoform-selective knockouts with spatially resolved cAMP sensors showed PDE4D and PDE4B operate in distinct subcellular cAMP pools, with PDE4D uniquely controlling bulk-cytosol cAMP and CREB transcription, establishing compartmentalized signaling.","evidence":"PDE4B and PDE4D knockout MEFs with FRET cAMP sensors, CREB reporters and isoproterenol stimulation; PKA feedback dissected with H89/PKI","pmids":["21288894","18508768"],"confidence":"High","gaps":["Molecular determinants restricting each enzyme to its pool not defined","How distinct pools couple to specific downstream effectors not mapped"]},{"year":2010,"claim":"Identified a defined signaling complex of PDE4D with EPAC1 at VE-cadherin junctions that controls endothelial barrier function, linking PDE4D scaffolding to vascular permeability.","evidence":"Reciprocal Co-IP, fractionation, cell-permeable EPAC1 peptide disruption and permeability assays in human arterial endothelial cells","pmids":["20732872"],"confidence":"High","gaps":["PDE4D isoform within the complex not specified","Whether catalytic activity or scaffolding drives the permeability effect not separated"]},{"year":2016,"claim":"Demonstrated that integrin α5 directly binds PDE4D5 and recruits PP2A-B55α to dephosphorylate inhibitory Ser651, activating the enzyme and driving atherosclerotic endothelial inflammation, linking matrix sensing to cAMP suppression.","evidence":"Integrin α5/α2 chimera knock-in mice, siRNA, Co-IP, Ser651 phospho-specific antibodies, cAMP measurement and in vivo inflammation assays; B55α confirmed by proteomics and in vitro phosphatase assay","pmids":["27595237","31408443"],"confidence":"High","gaps":["Whether other integrins use this PDE4D5 axis not tested","Stoichiometry and assembly order of the integrin-PDE4D5-PP2A complex not resolved"]},{"year":2015,"claim":"Extended the kinase regulation network by showing CaMKII activates PDE4D in cardiomyocytes, integrating Ca2+ and cAMP signaling as a negative feedback constraining beta-adrenergic cAMP.","evidence":"CaMKII inhibitor pharmacology, PDE4D activity assays and cAMP measurements in cardiomyocytes","pmids":["25646485"],"confidence":"Medium","gaps":["CaMKII phosphosite on PDE4D not mapped","Single-lab pharmacological approach without genetic confirmation"]},{"year":2012,"claim":"Human genetics established that heterozygous PDE4D loss-of-function mutations cause acrodysostosis without hormone resistance, defining a Mendelian disease arising from disrupted cAMP homeostasis in bone and CNS.","evidence":"Exome/Sanger sequencing of patients with zebrafish overexpression and morpholino knockdown producing mirror skeletal phenotypes; KO rat radiographic phenotyping and HEK293 catalytic assays","pmids":["24203977","22464252","22464250","25064455"],"confidence":"Medium","gaps":["Paradoxical low cAMP in patient cells from PDE4A/PDE4B compensation complicates genotype-phenotype interpretation","Affected bone/CNS cell types and developmental windows not defined"]},{"year":2025,"claim":"Established PDE4D as a driver of pathological remodeling in heart, liver, and cancer, acting through PKA-controlled YAP phosphorylation/degradation and CREB-SIRT1-mitophagy axes, defining therapeutic rationale for PDE4D inhibition.","evidence":"Gain/loss-of-function mouse models (cardiac haploinsufficiency, hepatic and AAV9 overexpression), Co-IP, YAP-S127A rescue, roflumilast treatment and pathway readouts across HCC, NAFLD/hypertension and heart failure models","pmids":["35597479","34826603","40015131","29386221"],"confidence":"Medium","gaps":["Whether the same isoform mediates effects across organs not resolved","Single-lab models for each disease context without independent replication"]},{"year":null,"claim":"It remains unresolved how the full repertoire of PDE4D isoforms, their distinct compartmental anchors, and the competing kinase/phosphatase inputs are integrated to shape tissue-specific cAMP microdomains in vivo.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking specific isoforms to specific cAMP pools across tissues","Anchor proteins for most particulate isoforms remain unidentified","In vivo dynamics of opposing PKA/ERK2/CaMKII/PP2A regulation not measured directly"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,2,6,18]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,6]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[2,3,19]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[19]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[3,11,12]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[3,31]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[10,11,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[13,14,23,25,27]}],"complexes":["PDE4D5-integrin α5-PP2A(B55α)","EPAC1-PDE4D-VE-cadherin","PDE4D5-RACK1-FAK"],"partners":["EPAC1","ITGA5","PPP2R2A","YAP1","HSPB6","RACK1","PTK2","MAPK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q08499","full_name":"3',5'-cyclic-AMP phosphodiesterase 4D","aliases":["DPDE3","PDE43","cAMP-specific phosphodiesterase 4D"],"length_aa":809,"mass_kda":91.1,"function":"Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes","subcellular_location":"Apical cell membrane; Cytoplasm; Membrane; Cytoplasm, cytoskeleton; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome","url":"https://www.uniprot.org/uniprotkb/Q08499/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PDE4D","classification":"Not Classified","n_dependent_lines":13,"n_total_lines":1208,"dependency_fraction":0.01076158940397351},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PDE4D","total_profiled":1310},"omim":[{"mim_id":"615668","title":"CHROMOSOME 5q12 DELETION SYNDROME","url":"https://www.omim.org/entry/615668"},{"mim_id":"614613","title":"ACRODYSOSTOSIS 2 WITH OR WITHOUT HORMONE RESISTANCE; ACRDYS2","url":"https://www.omim.org/entry/614613"},{"mim_id":"608117","title":"PHOSPHODIESTERASE 4D-INTERACTING PROTEIN; PDE4DIP","url":"https://www.omim.org/entry/608117"},{"mim_id":"606799","title":"STROKE, SUSCEPTIBILITY TO, 1","url":"https://www.omim.org/entry/606799"},{"mim_id":"604467","title":"MONOCYTE-TO-MACROPHAGE DIFFERENTIATION-ASSOCIATED PROTEIN; MMD","url":"https://www.omim.org/entry/604467"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Plasma membrane","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":70.7},{"tissue":"skeletal muscle","ntpm":63.5}],"url":"https://www.proteinatlas.org/search/PDE4D"},"hgnc":{"alias_symbol":[],"prev_symbol":["DPDE3"]},"alphafold":{"accession":"Q08499","domains":[{"cath_id":"1.10.1300.10","chopping":"389-710","consensus_level":"high","plddt":96.242,"start":389,"end":710}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q08499","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q08499-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q08499-F1-predicted_aligned_error_v6.png","plddt_mean":67.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PDE4D","jax_strain_url":"https://www.jax.org/strain/search?query=PDE4D"},"sequence":{"accession":"Q08499","fasta_url":"https://rest.uniprot.org/uniprotkb/Q08499.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q08499/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q08499"}},"corpus_meta":[{"pmid":"20037581","id":"PMC_20037581","title":"Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.","date":"2009","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20037581","citation_count":319,"is_preprint":false},{"pmid":"10828059","id":"PMC_10828059","title":"ERK2 mitogen-activated protein kinase binding, phosphorylation, and regulation of the PDE4D cAMP-specific phosphodiesterases. The involvement of COOH-terminal docking sites and NH2-terminal UCR regions.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10828059","citation_count":203,"is_preprint":false},{"pmid":"12377395","id":"PMC_12377395","title":"Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme.","date":"2002","source":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12377395","citation_count":194,"is_preprint":false},{"pmid":"10518565","id":"PMC_10518565","title":"Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10518565","citation_count":180,"is_preprint":false},{"pmid":"15731479","id":"PMC_15731479","title":"ALOX5AP gene and the PDE4D gene in a central European population of stroke patients.","date":"2005","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/15731479","citation_count":164,"is_preprint":false},{"pmid":"9371713","id":"PMC_9371713","title":"Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene.","date":"1997","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/9371713","citation_count":161,"is_preprint":false},{"pmid":"10841571","id":"PMC_10841571","title":"Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10841571","citation_count":136,"is_preprint":false},{"pmid":"15717866","id":"PMC_15717866","title":"Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.","date":"2005","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15717866","citation_count":118,"is_preprint":false},{"pmid":"14519662","id":"PMC_14519662","title":"PDE4D plays a critical role in the control of airway smooth muscle contraction.","date":"2003","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/14519662","citation_count":113,"is_preprint":false},{"pmid":"22464252","id":"PMC_22464252","title":"Exome sequencing identifies PDE4D mutations in acrodysostosis.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22464252","citation_count":110,"is_preprint":false},{"pmid":"22464250","id":"PMC_22464250","title":"Exome sequencing identifies PDE4D mutations as another cause of acrodysostosis.","date":"2012","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22464250","citation_count":104,"is_preprint":false},{"pmid":"18702734","id":"PMC_18702734","title":"Enhanced long-term potentiation and impaired learning in phosphodiesterase 4D-knockout (PDE4D) mice.","date":"2008","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18702734","citation_count":103,"is_preprint":false},{"pmid":"17404263","id":"PMC_17404263","title":"Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17404263","citation_count":102,"is_preprint":false},{"pmid":"12842049","id":"PMC_12842049","title":"Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity.","date":"2003","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/12842049","citation_count":95,"is_preprint":false},{"pmid":"23043190","id":"PMC_23043190","title":"PRKAR1A and PDE4D mutations cause acrodysostosis but two distinct syndromes with or without GPCR-signaling hormone resistance.","date":"2012","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23043190","citation_count":83,"is_preprint":false},{"pmid":"20732872","id":"PMC_20732872","title":"Cyclic AMP phosphodiesterase 4D (PDE4D) Tethers EPAC1 in a vascular endothelial cadherin (VE-Cad)-based signaling complex and controls cAMP-mediated vascular permeability.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20732872","citation_count":82,"is_preprint":false},{"pmid":"27595237","id":"PMC_27595237","title":"Interaction between integrin α5 and PDE4D regulates endothelial inflammatory signalling.","date":"2016","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/27595237","citation_count":81,"is_preprint":false},{"pmid":"19401450","id":"PMC_19401450","title":"Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen.","date":"2009","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/19401450","citation_count":81,"is_preprint":false},{"pmid":"9677395","id":"PMC_9677395","title":"Subcellular localization of rolipram-sensitive, cAMP-specific phosphodiesterases. Differential targeting and activation of the splicing variants derived from the PDE4D gene.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9677395","citation_count":77,"is_preprint":false},{"pmid":"21611147","id":"PMC_21611147","title":"β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21611147","citation_count":75,"is_preprint":false},{"pmid":"10187850","id":"PMC_10187850","title":"Phosphorylation-mediated activation and translocation of the cyclic AMP-specific phosphodiesterase PDE4D3 by cyclic AMP-dependent protein kinase and mitogen-activated protein kinases. A potential mechanism allowing for the coordinated regulation of PDE4D activity and targeting.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10187850","citation_count":74,"is_preprint":false},{"pmid":"23948935","id":"PMC_23948935","title":"RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-β42-induced memory deficits in mice.","date":"2014","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23948935","citation_count":71,"is_preprint":false},{"pmid":"30662799","id":"PMC_30662799","title":"miR-203a-3p promotes colorectal cancer proliferation and migration by targeting PDE4D.","date":"2018","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30662799","citation_count":70,"is_preprint":false},{"pmid":"10851231","id":"PMC_10851231","title":"Expression of phosphodiesterase 4D (PDE4D) is regulated by both the cyclic AMP-dependent protein kinase and mitogen-activated protein kinase signaling pathways. A potential mechanism allowing for the coordinated regulation of PDE4D activity and expression in cells.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10851231","citation_count":68,"is_preprint":false},{"pmid":"28054669","id":"PMC_28054669","title":"Comparison of the Pharmacological Profiles of Selective PDE4B and PDE4D Inhibitors in the Central Nervous System.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28054669","citation_count":63,"is_preprint":false},{"pmid":"25646485","id":"PMC_25646485","title":"A CaMKII/PDE4D negative feedback regulates cAMP signaling.","date":"2015","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/25646485","citation_count":57,"is_preprint":false},{"pmid":"29116166","id":"PMC_29116166","title":"Multiple Behavior Phenotypes of the Fragile-X Syndrome Mouse Model Respond to Chronic Inhibition of Phosphodiesterase-4D (PDE4D).","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29116166","citation_count":57,"is_preprint":false},{"pmid":"18420948","id":"PMC_18420948","title":"Variation in the PDE4D gene and ischemic stroke risk: a systematic review and meta-analysis on 5200 cases and 6600 controls.","date":"2008","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/18420948","citation_count":56,"is_preprint":false},{"pmid":"16543535","id":"PMC_16543535","title":"Evaluation of single nucleotide polymorphisms in the phosphodiesterase 4D gene (PDE4D) and their association with ischaemic stroke in a large German cohort.","date":"2006","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/16543535","citation_count":56,"is_preprint":false},{"pmid":"28760411","id":"PMC_28760411","title":"Polymorphisms of MTHFR, eNOS, ACE, AGT, ApoE, PON1, PDE4D, and Ischemic Stroke: Meta-Analysis.","date":"2017","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/28760411","citation_count":54,"is_preprint":false},{"pmid":"16020760","id":"PMC_16020760","title":"Linkage of ischemic stroke to the PDE4D region on 5q in a Swedish population.","date":"2005","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/16020760","citation_count":53,"is_preprint":false},{"pmid":"24203977","id":"PMC_24203977","title":"Different mutations in PDE4D associated with developmental disorders with mirror phenotypes.","date":"2013","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24203977","citation_count":52,"is_preprint":false},{"pmid":"21288894","id":"PMC_21288894","title":"PDE4D and PDE4B function in distinct subcellular compartments in mouse embryonic fibroblasts.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21288894","citation_count":51,"is_preprint":false},{"pmid":"19371330","id":"PMC_19371330","title":"The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release.","date":"2009","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19371330","citation_count":51,"is_preprint":false},{"pmid":"29386221","id":"PMC_29386221","title":"Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29386221","citation_count":49,"is_preprint":false},{"pmid":"12834813","id":"PMC_12834813","title":"Cloning and characterization of novel PDE4D isoforms PDE4D6 and PDE4D7.","date":"2003","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/12834813","citation_count":46,"is_preprint":false},{"pmid":"19786079","id":"PMC_19786079","title":"Association of PDE4D and IL-1 gene polymorphism with ischemic stroke in a Han Chinese population.","date":"2010","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/19786079","citation_count":46,"is_preprint":false},{"pmid":"31408443","id":"PMC_31408443","title":"Integrin α5β1 regulates PP2A complex assembly through PDE4D in atherosclerosis.","date":"2019","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/31408443","citation_count":46,"is_preprint":false},{"pmid":"16825591","id":"PMC_16825591","title":"Polymorphisms of the phosphodiesterase 4D, cAMP-specific (PDE4D) gene and risk of ischemic stroke: a prospective, nested case-control evaluation.","date":"2006","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/16825591","citation_count":46,"is_preprint":false},{"pmid":"23033274","id":"PMC_23033274","title":"Identification of novel mutations confirms PDE4D as a major gene causing acrodysostosis.","date":"2012","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/23033274","citation_count":46,"is_preprint":false},{"pmid":"12125047","id":"PMC_12125047","title":"Differential distribution of PDE4D splice variant mRNAs in rat brain suggests association with specific pathways and presynaptical localization.","date":"2002","source":"Synapse (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/12125047","citation_count":46,"is_preprint":false},{"pmid":"25064455","id":"PMC_25064455","title":"Heterozygous mutations in cyclic AMP phosphodiesterase-4D (PDE4D) and protein kinase A (PKA) provide new insights into the molecular pathology of acrodysostosis.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25064455","citation_count":43,"is_preprint":false},{"pmid":"15302115","id":"PMC_15302115","title":"The induction of cyclic nucleotide phosphodiesterase 4 gene (PDE4D) impairs memory in a water maze task.","date":"2004","source":"Behavioural brain research","url":"https://pubmed.ncbi.nlm.nih.gov/15302115","citation_count":41,"is_preprint":false},{"pmid":"20540798","id":"PMC_20540798","title":"Sex-differential genetic effect of phosphodiesterase 4D (PDE4D) on carotid atherosclerosis.","date":"2010","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20540798","citation_count":40,"is_preprint":false},{"pmid":"24998378","id":"PMC_24998378","title":"Discovery of triazines as selective PDE4B versus PDE4D inhibitors.","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/24998378","citation_count":40,"is_preprint":false},{"pmid":"17655870","id":"PMC_17655870","title":"PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden.","date":"2007","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/17655870","citation_count":39,"is_preprint":false},{"pmid":"26763073","id":"PMC_26763073","title":"Screening of PRKAR1A and PDE4D in a Large Italian Series of Patients Clinically Diagnosed With Albright Hereditary Osteodystrophy and/or Pseudohypoparathyroidism.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/26763073","citation_count":39,"is_preprint":false},{"pmid":"8797812","id":"PMC_8797812","title":"Identification of cyclic AMP-phosphodiesterase variants from the PDE4D gene expressed in human peripheral mononuclear cells.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8797812","citation_count":39,"is_preprint":false},{"pmid":"16162858","id":"PMC_16162858","title":"Familial aggregation, the PDE4D gene, and ischemic stroke in a genetically isolated population.","date":"2005","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16162858","citation_count":38,"is_preprint":false},{"pmid":"16956605","id":"PMC_16956605","title":"Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.","date":"2006","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/16956605","citation_count":38,"is_preprint":false},{"pmid":"18705898","id":"PMC_18705898","title":"Stroke genetics--focus on PDE4D gene.","date":"2008","source":"International journal of stroke : official journal of the International Stroke Society","url":"https://pubmed.ncbi.nlm.nih.gov/18705898","citation_count":36,"is_preprint":false},{"pmid":"33363155","id":"PMC_33363155","title":"A Novel PDE4D Inhibitor BPN14770 Reverses Scopolamine-Induced Cognitive Deficits via cAMP/SIRT1/Akt/Bcl-2 Pathway.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33363155","citation_count":36,"is_preprint":false},{"pmid":"18508768","id":"PMC_18508768","title":"Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18508768","citation_count":36,"is_preprint":false},{"pmid":"27560284","id":"PMC_27560284","title":"New insights into selective PDE4D inhibitors: 3-(Cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) oxime (GEBR-7b) structural development and promising activities to restore memory impairment.","date":"2016","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27560284","citation_count":33,"is_preprint":false},{"pmid":"34630853","id":"PMC_34630853","title":"circ_0023461 Silencing Protects Cardiomyocytes from Hypoxia-Induced Dysfunction through Targeting miR-370-3p/PDE4D Signaling.","date":"2021","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/34630853","citation_count":31,"is_preprint":false},{"pmid":"19608201","id":"PMC_19608201","title":"Phosphodiesterase 4D (PDE4D) gene variants and the risk of ischemic stroke in a South Indian population.","date":"2009","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/19608201","citation_count":31,"is_preprint":false},{"pmid":"7835077","id":"PMC_7835077","title":"Chromosomal localization of the human and rat genes (PDE4D and PDE4B) encoding the cAMP-specific phosphodiesterases 3 and 4.","date":"1995","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/7835077","citation_count":31,"is_preprint":false},{"pmid":"28092671","id":"PMC_28092671","title":"PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28092671","citation_count":30,"is_preprint":false},{"pmid":"20182758","id":"PMC_20182758","title":"Meta-analysis of association between variation in the PDE4D gene and ischemic cerebral infarction risk in Asian populations.","date":"2010","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/20182758","citation_count":30,"is_preprint":false},{"pmid":"19246712","id":"PMC_19246712","title":"Lack of association between variations of PDE4D and ischemic stroke in the Japanese population.","date":"2009","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/19246712","citation_count":30,"is_preprint":false},{"pmid":"34826603","id":"PMC_34826603","title":"Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.","date":"2021","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/34826603","citation_count":29,"is_preprint":false},{"pmid":"18006274","id":"PMC_18006274","title":"Identification and characterization of novel mouse PDE4D isoforms: molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals.","date":"2007","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/18006274","citation_count":29,"is_preprint":false},{"pmid":"26562185","id":"PMC_26562185","title":"PDE4D phosphorylation: A coincidence detector integrating multiple signaling pathways.","date":"2015","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/26562185","citation_count":28,"is_preprint":false},{"pmid":"25426411","id":"PMC_25426411","title":"Targeted disruption of the heat shock protein 20-phosphodiesterase 4D (PDE4D) interaction protects against pathological cardiac remodelling in a mouse model of hypertrophy.","date":"2014","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/25426411","citation_count":27,"is_preprint":false},{"pmid":"21677445","id":"PMC_21677445","title":"Meta-analysis of homogeneous subgroups reveals association between PDE4D gene variants and ischemic stroke.","date":"2011","source":"Neuroepidemiology","url":"https://pubmed.ncbi.nlm.nih.gov/21677445","citation_count":26,"is_preprint":false},{"pmid":"18398440","id":"PMC_18398440","title":"Ischaemic stroke in hypertensive patients is associated with variations in the PDE4D genome region.","date":"2008","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/18398440","citation_count":26,"is_preprint":false},{"pmid":"26335809","id":"PMC_26335809","title":"PDK1/Akt/PDE4D axis identified as a target for asthma remedy synergistic with β2 AR agonists by a natural agent arctigenin.","date":"2015","source":"Allergy","url":"https://pubmed.ncbi.nlm.nih.gov/26335809","citation_count":26,"is_preprint":false},{"pmid":"26671126","id":"PMC_26671126","title":"Phosphodiesterase4D (PDE4D)--A risk factor for atrial fibrillation and stroke?","date":"2015","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26671126","citation_count":25,"is_preprint":false},{"pmid":"30006632","id":"PMC_30006632","title":"Expanding the phenotypic spectrum of variants in PDE4D/PRKAR1A: from acrodysostosis to acroscyphodysplasia.","date":"2018","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/30006632","citation_count":23,"is_preprint":false},{"pmid":"35597479","id":"PMC_35597479","title":"PDE4D binds and interacts with YAP to cooperatively promote HCC progression.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35597479","citation_count":22,"is_preprint":false},{"pmid":"37767771","id":"PMC_37767771","title":"Resveratrol prevents Drp1-mediated mitochondrial fission in the diabetic kidney through the PDE4D/PKA pathway.","date":"2023","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/37767771","citation_count":22,"is_preprint":false},{"pmid":"19196240","id":"PMC_19196240","title":"Association between the PDE4D gene and ischaemic stroke in the Chinese Han population.","date":"2009","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/19196240","citation_count":22,"is_preprint":false},{"pmid":"17215491","id":"PMC_17215491","title":"Expression of the cAMP-phosphodiesterase PDE4D isoforms and age-related changes in follicle-stimulating hormone-stimulated PDE4 activities in immature rat sertoli cells.","date":"2007","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/17215491","citation_count":22,"is_preprint":false},{"pmid":"27683107","id":"PMC_27683107","title":"Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27683107","citation_count":22,"is_preprint":false},{"pmid":"21989204","id":"PMC_21989204","title":"Association of the phosphodiesterase 4D (PDE4D) gene and cardioembolic stroke in an Australian cohort.","date":"2011","source":"International journal of stroke : official journal of the International Stroke Society","url":"https://pubmed.ncbi.nlm.nih.gov/21989204","citation_count":22,"is_preprint":false},{"pmid":"26004910","id":"PMC_26004910","title":"Association between PDE4D gene and ischemic stroke: recent advancements.","date":"2015","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26004910","citation_count":21,"is_preprint":false},{"pmid":"29497131","id":"PMC_29497131","title":"PDE4D regulates Spine Plasticity and Memory in the Retrosplenial Cortex.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/29497131","citation_count":21,"is_preprint":false},{"pmid":"33328902","id":"PMC_33328902","title":"Mapping Phosphodiesterase 4D (PDE4D) in Macaque Dorsolateral Prefrontal Cortex: Postsynaptic Compartmentalization in Layer III Pyramidal Cell Circuits.","date":"2020","source":"Frontiers in neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/33328902","citation_count":21,"is_preprint":false},{"pmid":"40015131","id":"PMC_40015131","title":"PDE4D inhibition ameliorates cardiac hypertrophy and heart failure by activating mitophagy.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/40015131","citation_count":20,"is_preprint":false},{"pmid":"22487514","id":"PMC_22487514","title":"A new model of Pde4d deficiency: genetic knock-down of PDE4D enzyme in rats produces an antidepressant phenotype without spatial cognitive effects.","date":"2012","source":"Genes, brain, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/22487514","citation_count":20,"is_preprint":false},{"pmid":"30482227","id":"PMC_30482227","title":"Inhibition of TPL2 by interferon-α suppresses bladder cancer through activation of PDE4D.","date":"2018","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/30482227","citation_count":20,"is_preprint":false},{"pmid":"33519668","id":"PMC_33519668","title":"Long Non-coding RNAMALAT1 Knockdown Alleviates Cerebral Ischemia/Reperfusion Injury of Rats Through Regulating the miR-375/PDE4D Axis.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33519668","citation_count":17,"is_preprint":false},{"pmid":"37196909","id":"PMC_37196909","title":"PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes.","date":"2023","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/37196909","citation_count":16,"is_preprint":false},{"pmid":"22771915","id":"PMC_22771915","title":"Association of SNP41, SNP56 and a novel SNP in PDE4D gene with stroke and its subtypes.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22771915","citation_count":16,"is_preprint":false},{"pmid":"25126889","id":"PMC_25126889","title":"Synthesis, biological evaluation, and molecular modeling of new 3-(cyclopentyloxy)-4-methoxybenzaldehyde O-(2-(2,6-dimethylmorpholino)-2-oxoethyl) Oxime (GEBR-7b) related phosphodiesterase 4D (PDE4D) inhibitors.","date":"2014","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25126889","citation_count":16,"is_preprint":false},{"pmid":"35196602","id":"PMC_35196602","title":"PDE4D targeting enhances anti-tumor effects of sorafenib in clear cell renal cell carcinoma and attenuates MAPK/ERK signaling in a CRAF-dependent manner.","date":"2022","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35196602","citation_count":15,"is_preprint":false},{"pmid":"22274584","id":"PMC_22274584","title":"A large-sample assessment of possible association between ischaemic stroke and rs12188950 in the PDE4D gene.","date":"2012","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/22274584","citation_count":15,"is_preprint":false},{"pmid":"23799094","id":"PMC_23799094","title":"Genetic polymorphism in PDE4D gene and risk of ischemic stroke in Chinese population: a meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23799094","citation_count":15,"is_preprint":false},{"pmid":"29234926","id":"PMC_29234926","title":"Association between PDE4D rs966221 polymorphism and risk of ischemic stroke: a systematic review and meta-analysis.","date":"2017","source":"Metabolic brain disease","url":"https://pubmed.ncbi.nlm.nih.gov/29234926","citation_count":13,"is_preprint":false},{"pmid":"36979232","id":"PMC_36979232","title":"Moderate-Intensity Intermittent Training Alters the DNA Methylation Pattern of PDE4D Gene in Hippocampus to Improve the Ability of Spatial Learning and Memory in Aging Rats Reduced by D-Galactose.","date":"2023","source":"Brain sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36979232","citation_count":13,"is_preprint":false},{"pmid":"31303835","id":"PMC_31303835","title":"Association between PDE4D polymorphism and ischemic stroke in young population.","date":"2019","source":"Saudi journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31303835","citation_count":13,"is_preprint":false},{"pmid":"33192469","id":"PMC_33192469","title":"Phosphodiesterase PDE4D Is Decreased in Frontal Cortex of Aged Rats and Positively Correlated With Working Memory Performance and Inversely Correlated With PKA Phosphorylation of Tau.","date":"2020","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/33192469","citation_count":13,"is_preprint":false},{"pmid":"38006681","id":"PMC_38006681","title":"Baicalein promotes the microglia M2 polarization and suppresses apoptosis by targeting HMOX1/PDE4D to alleviate Alzheimer's disease.","date":"2023","source":"Immunobiology","url":"https://pubmed.ncbi.nlm.nih.gov/38006681","citation_count":13,"is_preprint":false},{"pmid":"36252429","id":"PMC_36252429","title":"Circ_0101874 overexpression strengthens PDE4D expression by targeting miR-335-5p to promote neuronal injury in ischemic stroke.","date":"2022","source":"Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association","url":"https://pubmed.ncbi.nlm.nih.gov/36252429","citation_count":12,"is_preprint":false},{"pmid":"18220751","id":"PMC_18220751","title":"PDE4D gene in the STRK1 region on 5q12: susceptibility gene for ischemic stroke.","date":"2007","source":"Current medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18220751","citation_count":12,"is_preprint":false},{"pmid":"37729023","id":"PMC_37729023","title":"Endoplasmic reticulum stress in pancreatic β cells induces incretin desensitization and β-cell dysfunction via ATF4-mediated PDE4D expression.","date":"2023","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/37729023","citation_count":12,"is_preprint":false},{"pmid":"16635437","id":"PMC_16635437","title":"Role of FLAP and PDE4D in myocardial infarction and stroke: target discovery and future treatment options.","date":"2006","source":"Current treatment options in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16635437","citation_count":12,"is_preprint":false},{"pmid":"27546041","id":"PMC_27546041","title":"Further Insights in the Binding Mode of Selective Inhibitors to Human PDE4D Enzyme Combining Docking and Molecular Dynamics.","date":"2016","source":"Molecular informatics","url":"https://pubmed.ncbi.nlm.nih.gov/27546041","citation_count":12,"is_preprint":false},{"pmid":"34171658","id":"PMC_34171658","title":"Design, synthesis, biological evaluation and structural characterization of novel GEBR library PDE4D inhibitors.","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34171658","citation_count":12,"is_preprint":false},{"pmid":"37722608","id":"PMC_37722608","title":"Resveratrol ameliorates diabetic encephalopathy through PDE4D/PKA/Drp1 signaling.","date":"2023","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/37722608","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52700,"output_tokens":9222,"usd":0.148215,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19566,"output_tokens":4843,"usd":0.109452,"stage2_stop_reason":"end_turn"},"total_usd":0.257667,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2009,\n      \"finding\": \"Co-crystal structures of PDE4D with inhibitors reveal that the regulatory domain (UCR2/CR3) closes across the active site, establishing the structural basis of allosteric regulation. Mutagenesis and kinetic studies confirmed that small-molecule allosteric modulators binding this closed conformation partially inhibit enzymatic activity (Imax ~80-90%) without fully blocking cAMP hydrolysis.\",\n      \"method\": \"X-ray co-crystallography (7 structures), site-directed mutagenesis, enzyme kinetics, cellular cAMP assays, in vivo emesis models\",\n      \"journal\": \"Nature biotechnology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple crystal structures with mutagenesis and kinetic validation in one rigorous study\",\n      \"pmids\": [\"20037581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"ERK2 phosphorylates PDE4D3 at Ser579 using FQF and KIM docking sites flanking the target residue; mutation of either docking site prevents ERK2 co-immunoprecipitation with PDE4D3, ablates EGF-mediated inhibition of PDE4D3 in transfected cells, and attenuates in vitro phosphorylation. The long-isoform UCR1/UCR2 regulatory module amplifies the inhibitory effect of ERK2 phosphorylation on the catalytic unit, whereas in the short isoform PDE4D1 (containing only UCR2), ERK2 phosphorylation activates the enzyme. Thus PDE4D encodes isoenzymes that are either inhibited or activated by ERK2.\",\n      \"method\": \"Site-directed mutagenesis of docking sites, co-immunoprecipitation, in vitro ERK2 kinase assay, transfected COS cell cAMP assay, truncation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — in vitro phosphorylation assay with mutagenesis, reciprocal Co-IP, cellular functional readout in one study\",\n      \"pmids\": [\"10828059\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The N-terminal unique regions of PDE4D3, PDE4D4, and PDE4D5 (derived from alternatively spliced exons) determine their subcellular localization: PDE4D1 and PDE4D2 are cytosolic only, while PDE4D3/4/5 partition between cytosolic and particulate fractions. Particulate forms of PDE4D3 and PDE4D5 show 2-7-fold higher IC50 for rolipram than their cytosolic counterparts.\",\n      \"method\": \"Transient expression in COS-7 cells, subcellular fractionation, immunoblotting of human cell lines and rat brain, rolipram IC50 determination\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — fractionation with functional inhibitor-sensitivity readout, replicated across five isoforms and native tissues\",\n      \"pmids\": [\"9371713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PDE4D splice variants are targeted to discrete subcellular compartments in thyroid FRTL-5 cells: PDE4D3 is recovered in both soluble and particulate fractions and is solubilized by nonionic detergent, whereas PDE4D4 requires ionic detergent, indicating different anchoring mechanisms. TSH stimulation causes PKA-dependent electrophoretic mobility shift (phosphorylation) and activation of PDE4D3, and long-term TSH induces PDE4D2 expression in the soluble fraction. Immunofluorescence localizes PDE4D signal to plasma-membrane-adjacent cytoskeletal structures and a perinuclear region.\",\n      \"method\": \"Subcellular fractionation, differential detergent extraction, immunoblotting, immunofluorescence microscopy, TSH/cAMP stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (fractionation, detergent extraction, immunofluorescence) with hormone-regulated functional consequence\",\n      \"pmids\": [\"9677395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PKA phosphorylates and activates PDE4D3 and PDE4D5 in vascular smooth muscle cells (VSMCs) in response to elevated cAMP. PKC-Raf-MEK-ERK activation also phosphorylates and activates PDE4D3 in VSMCs. Simultaneous activation of both PKA and PKC-Raf-MEK-ERK causes coordinated activation of PDE4D3 and translocation of particulate PDE4D3 to the cytosolic fraction.\",\n      \"method\": \"Pharmacological inhibitors (PKA, MEK), biochemical fractionation, in-cell phosphorylation assays in VSMCs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal activation pathways demonstrated with pharmacological + biochemical approaches, single lab\",\n      \"pmids\": [\"10187850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PKA-dependent elevation of cAMP induces expression of PDE4D1 and PDE4D2 in VSMCs (feedback induction). Simultaneous activation of PKC-Raf-MEK-ERK blunts this cAMP-mediated induction of PDE4D through a mechanism involving decreased PDE4D mRNA stability, thereby attenuating cAMP desensitization.\",\n      \"method\": \"mRNA stability assays, pharmacological inhibitors (PKA, MEK, PKC), quantitative RT-PCR, immunoblotting in VSMCs\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mRNA stability mechanistic follow-up with pharmacological tools, single lab\",\n      \"pmids\": [\"10851231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Crystal structures of the PDE4D2 catalytic domain complexed with (R)- or (R,S)-rolipram reveal that inhibitor selectivity is determined by the chemical nature of active-site residues and subtle conformational changes of the binding pocket; Gln369 conformation plays a key role in inhibitor recognition.\",\n      \"method\": \"X-ray crystallography of PDE4D2 catalytic domain–rolipram complexes, structural comparison with PDE5/PDE7\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with mechanistic interpretation of selectivity determinants\",\n      \"pmids\": [\"12842049\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Genetic inactivation of PDE4D in mice (PDE4D−/−) reduces total PDE4 activity and causes impaired ovulation and diminished gonadotropin sensitivity of granulosa cells, delayed growth, and reduced viability, demonstrating that PDE4D-mediated cAMP hydrolysis is required for normal gonadotropin signaling, growth, and fertility.\",\n      \"method\": \"Gene knockout mouse model, immunoblotting, PDE4 activity assay, ovulation and fertility phenotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with defined cellular phenotype (granulosa cell gonadotropin sensitivity) and biochemical confirmation of enzyme loss\",\n      \"pmids\": [\"10518565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"PDE4D−/− mouse airways are refractory to muscarinic cholinergic stimulation; muscarinic receptor-mediated decrease of cAMP is absent, and antigen-induced airway hyperreactivity is abolished despite normal inflammatory infiltration. The loss of response is airway-specific (not observed in heart), establishing PDE4D as essential for cAMP homeostasis and cholinergic signaling in airway.\",\n      \"method\": \"PDE4D−/− mouse model, airway resistance measurements, cAMP accumulation assays, antigen challenge model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with tissue-specific functional readout and biochemical cAMP measurement\",\n      \"pmids\": [\"10841571\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PDE4D−/− tracheas show 60% reduction in maximal cholinergic-evoked tension and five-fold decreased sensitivity to muscarinic agonists, with preserved responses to KCl and arginine vasopressin, identifying a specific role for PDE4D in muscarinic smooth muscle contraction. Elevated cAMP in PDE4D−/− airway leads to increased prostanoid (PGE2) accumulation; blockade of prostanoid synthesis restores muscarinic responses in vitro and in vivo.\",\n      \"method\": \"Isolated trachea contractility assays (PDE4D−/− vs WT), cAMP accumulation, prostanoid inhibition rescue experiments, in vivo airway measurements\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with pharmacological rescue establishing mechanistic pathway, multiple readouts\",\n      \"pmids\": [\"14519662\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ablation of PDE4D (but not PDE4A or PDE4B) in mouse embryonic fibroblasts markedly enhances beta2-adrenergic receptor (beta2AR)-induced PDE activation, prolongs cAMP accumulation and CREB phosphorylation, and delays return to basal cAMP levels. This effect is largely due to loss of a PKA-mediated negative feedback loop (PKA activates PDE4D to terminate the cAMP signal). PDE4D ablation also alters beta2AR desensitization kinetics and the receptor's interaction with Gαi.\",\n      \"method\": \"PDE4D/4A/4B knockout MEFs, cAMP accumulation assays, CREB phosphorylation, PKA inhibitors (H89/PKI), beta2AR desensitization and Gαi co-immunoprecipitation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform-selective KO MEFs with multiple orthogonal biochemical readouts establishing negative feedback mechanism\",\n      \"pmids\": [\"18508768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE4D ablation in mouse embryonic fibroblasts enhances agonist-induced cAMP in the bulk cytosol and at the plasma membrane, whereas PDE4B ablation specifically elevates cAMP in a near-membrane pool without affecting bulk cytosol cAMP. PDE4D (but not PDE4B) ablation significantly prolongs CREB-mediated transcription. These results establish that PDE4D and PDE4B function in distinct subcellular cAMP compartments.\",\n      \"method\": \"PDE4B and PDE4D knockout MEFs, FRET-based cAMP sensors (cytosol and near-membrane), CREB-reporter assays, isoproterenol stimulation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with spatially resolved FRET cAMP measurements and transcriptional readout, multiple compartments tested\",\n      \"pmids\": [\"21288894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PDE4D enzymes form a complex with EPAC1 at vascular endothelial cadherin (VE-Cad)-based intercellular junctions in human arterial endothelial cells. Protein–protein interactions between EPAC1 and PDE4D are required for their integration into VE-Cad complexes. Disruption of this interaction with a cell-permeable EPAC1 peptide antagonizes EPAC1–PDE4D binding and directly alters vascular permeability.\",\n      \"method\": \"Co-immunoprecipitation, biochemical fractionation, peptide competition assay, VE-cadherin complex isolation, permeability assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP with functional peptide-disruption readout establishing a defined signaling complex\",\n      \"pmids\": [\"20732872\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"On fibronectin matrix, integrin α5 directly binds PDE4D5 and recruits PP2A (via B55α regulatory subunit) to dephosphorylate PDE4D5 at the inhibitory site Ser651, thereby activating the phosphodiesterase, suppressing cAMP, and promoting endothelial inflammatory signaling. In vivo knockdown of PDE4D5 inhibits inflammation at atherosclerosis-prone arterial sites.\",\n      \"method\": \"Integrin α5/α2 chimera knock-in mice, siRNA knockdown, Co-IP, phospho-specific antibodies (Ser651), cAMP measurement, in vivo endothelial inflammation assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — integrin chimera knock-in with biochemical mechanism (PP2A dephosphorylation site identified), in vivo validation\",\n      \"pmids\": [\"27595237\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The PP2A regulatory subunit B55α recruits PP2A to PDE4D5, directly dephosphorylating PDE4D5 at Ser651 (activating it) at focal adhesions. This PDE4D5-B55α-PP2A complex also dephosphorylates and activates YAP. Mutation of the integrin α5 binding site in PDE4D5 reduces endothelial inflammatory activation and atherosclerotic plaque size in a hyperlipidemic mouse model.\",\n      \"method\": \"Proteomics (mass spectrometry identification of B55α), Co-IP, in vitro phosphatase assay, PDE4D5 integrin-binding site knock-in mouse, atherosclerosis plaque quantification\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — proteomics-identified binding partner confirmed by Co-IP and in vitro phosphatase assay, in vivo knock-in model with disease readout\",\n      \"pmids\": [\"31408443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CaMKII phosphorylates and activates PDE4D in cardiomyocytes in response to beta-adrenergic receptor stimulation, establishing a negative feedback loop that constrains basal and beta-AR-stimulated cAMP levels. This CaMKII→PDE4D axis integrates cAMP/PKA and Ca2+/CaMKII signaling pathways.\",\n      \"method\": \"CaMKII inhibitor pharmacology, PDE4D activity assays, cAMP measurements in cardiomyocytes, CaMKII activation/inhibition experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cellular kinase assay and cAMP measurements, single lab with pharmacological approach\",\n      \"pmids\": [\"25646485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Phosphorylated HSP20 forms a complex with PDE4D in cardiomyocytes; peptide disruption of the HSP20–PDE4D interaction in human iPSC-derived cardiomyocytes attenuates action potential prolongation, and in a mouse pressure-overload model protects against adverse cardiac remodeling (improved contractility, reduced hypertrophy and fibrosis).\",\n      \"method\": \"Peptide disruption, human iPSC-cardiomyocytes electrophysiology, mouse pressure-overload hypertrophy model, cardiac histology and contractility\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — peptide disruption with defined complex and in vivo cardiac phenotype, single lab\",\n      \"pmids\": [\"25426411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PDE4D5 isoform interacts with focal adhesion kinase (FAK) through the scaffolding protein RACK1 in BRAF-mutated melanoma cells; inhibition of PDE4D enzymatic activity or disruption of the PDE4D–FAK interaction reduces melanoma cell invasion in vitro.\",\n      \"method\": \"Co-immunoprecipitation (PDE4D5–RACK1–FAK), PDE4 pharmacological inhibitors, invasion assays, patient tissue detection by proximity ligation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — Co-IP establishing ternary complex with functional invasion readout, single lab\",\n      \"pmids\": [\"28092671\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PDE4D6 (supershort) and PDE4D7 (long) isoforms hydrolyze cAMP with high affinity and are inhibited by rolipram. PDE4D7 activity is elevated by PKA-dependent phosphorylation at the conserved UCR1 site, whereas PDE4D6 (lacking UCR1) is not activated by PKA.\",\n      \"method\": \"Baculovirus expression of recombinant PDE4D6/7, enzyme kinetics, PKA phosphorylation assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro enzyme assay with recombinant protein, single lab\",\n      \"pmids\": [\"12834813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"In mouse embryonic fibroblasts, short PDE4D1 isoforms localize to the nucleus via a nuclear localization signal in the unique N-terminal region, while supershort isoforms (PDE4D2, PDE4D6, PDE4D10) are restricted to the cytoplasm. Deletion of the N-terminus of PDE4D1 abolishes nuclear targeting.\",\n      \"method\": \"Subcellular fractionation, deletion mutagenesis, immunofluorescence microscopy\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — localization by fractionation and immunofluorescence with deletion mutant validation, single lab\",\n      \"pmids\": [\"18006274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PDE4D controls GLP-1 release in GLUTag cells: rolipram enhances GLP-1 release in vivo (rats) and in vitro. Stable overexpression of catalytically-inactive D556A-PDE4D5 mutant elevates cAMP and increases basal and glucose-induced GLP-1 release; PKA inhibitor H89 partially blocks this increase, establishing that PDE4D4/5 regulates GLP-1 secretion via cAMP/PKA.\",\n      \"method\": \"PDE4 inhibitor (rolipram) in vivo and in vitro, stable overexpression of catalytically inactive PDE4D5 mutant, PKA inhibitor H89, GLP-1 ELISA\",\n      \"journal\": \"British journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative mutant overexpression with pharmacological rescue, single lab\",\n      \"pmids\": [\"19371330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Transposon insertional mutagenesis in mouse prostate identified PDE4D as a proliferation-promoting factor; knockdown of PDE4D reduced growth and migration of human prostate cancer cells in vitro and reduced tumor xenograft growth in vivo.\",\n      \"method\": \"Sleeping Beauty transposon somatic mutagenesis screen, siRNA knockdown, in vitro proliferation/migration assays, xenograft tumor growth assay\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional KD with in vitro and in vivo growth readouts, single lab\",\n      \"pmids\": [\"19401450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Acrodysostosis-associated PDE4D missense mutations (Gly673Asp and Ile678Thr) reduce catalytic activity in vitro; ectopic expression in HEK293 cells confirms reduced PDE4D activity by elevated cAMP. However, patient-derived cells paradoxically show low cAMP due to compensatory upregulation of PDE4A and PDE4B. PDE4D-knockout rats have shorter metacarpals and phalanges consistent with acrodysostosis.\",\n      \"method\": \"3D structural modeling, in vitro cAMP accumulation assay in HEK293 cells, patient-derived cell cAMP measurement, immunoblotting, PDE4D-KO rat radiographic phenotyping\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ectopic expression functional assay plus KO rat phenotyping, multiple methods but single lab\",\n      \"pmids\": [\"25064455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Heterozygous de novo missense mutations in PDE4D cause acrodysostosis (skeletal dysplasia, brachydactyly, nasal hypoplasia, intellectual disability) without hormone resistance, establishing that PDE4D loss-of-function disrupts cAMP homeostasis in bone and CNS. Functional assay confirmed by zebrafish: overexpression of mutated PDE4D mRNA and morpholino-based pde4d knockdown produce mirror skeletal phenotypes, validating the pathogenicity of point mutations.\",\n      \"method\": \"Exome sequencing, Sanger sequencing, zebrafish overexpression and morpholino knockdown, array CGH\",\n      \"journal\": \"Journal of medical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — zebrafish functional assay with both gain- and loss-of-function, confirmed by multiple human genetic studies\",\n      \"pmids\": [\"24203977\", \"22464252\", \"22464250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Hepatic overexpression of PDE4D in mice induces NAFLD and hypertension via activation of fatty acid translocase CD36 signaling, leading to hepatocyte TGF-β1 production and vascular TGF-β1 signaling. siRNA silencing of TGF-β1 in hepatocytes normalizes the hypertension caused by PDE4D overexpression, placing PDE4D upstream of CD36–TGF-β1 in a liver-to-vessel axis.\",\n      \"method\": \"Hepatic PDE4D overexpression (adenovirus), liver-targeted TGF-β1 siRNA nanoparticles, hepatic steatosis histology, blood pressure measurement, CD36 signaling assays\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function overexpression with pathway-specific rescue (TGF-β1 siRNA), single lab\",\n      \"pmids\": [\"34826603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PDE4D physically binds YAP in hepatocellular carcinoma cells; PDE4D overexpression increases YAP dephosphorylation and transcriptional activity to promote HCC growth. Roflumilast-mediated PDE4D inhibition activates cAMP-PKA, causing PKA-dependent YAP phosphorylation at Ser127 and YAP degradation. YAP-S127A mutant reverses roflumilast-mediated suppression, confirming PDE4D acts via PKA→YAP-S127.\",\n      \"method\": \"Co-immunoprecipitation (PDE4D–YAP), overexpression and knockdown, phospho-YAP(S127) immunoblotting, YAP-S127A rescue, roflumilast treatment, in vivo xenograft\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP establishing interaction, mutant rescue pinpointing mechanistic site, in vivo confirmation; single lab\",\n      \"pmids\": [\"35597479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In pancreatic β cells, endoplasmic reticulum stress activates the PERK-ATF4 pathway, which transcriptionally induces PDE4D expression, reducing cAMP signaling and impairing incretin-stimulated insulin secretion. Pharmacological inhibition of ATF4 reduces PDE4D expression and restores β-cell function in db/db mice; PDE4D inhibition similarly rescues β-cell function in ATF4-transgenic and db/db mice.\",\n      \"method\": \"ATF4 transgenic mice, db/db mice, ATF4 pathway inhibitor, PDE4 inhibitor, cAMP measurement, glucose tolerance and insulin secretion assays, nuclear localization studies\",\n      \"journal\": \"American journal of physiology. Endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ATF4 transgenic plus pharmacological rescue in two mouse models establishing transcriptional regulation, single lab\",\n      \"pmids\": [\"37729023\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PDE4D is upregulated in failing hearts via isoproterenol-stimulated cAMP-PKA signaling. PDE4D overexpression suppresses CREB-SIRT1 signaling and PINK1/Parkin-mediated mitophagy, causing oxidative stress and cardiomyocyte hypertrophy; PDE4D knockdown or roflumilast reverses these effects. Cardiac-specific PDE4D haploinsufficiency protects against TAC-induced cardiac hypertrophy and heart failure in vivo; PDE4D overexpression abolishes this protection.\",\n      \"method\": \"Global and cardiac-specific PDE4D heterozygous KO mice, AAV9-PDE4D overexpression, TAC and isoproterenol mouse models, mitophagy assays (PINK1/Parkin), CREB-SIRT1 pathway immunoblotting, roflumilast treatment\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO plus overexpression with mechanistic pathway readout (CREB-SIRT1-mitophagy), single lab\",\n      \"pmids\": [\"40015131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Arctigenin binds PDK1 (identified by chemical proteomics capture) and inhibits PDK1 kinase activity, leading to reduced Akt-mediated phosphorylation of PDE4D in human bronchial smooth muscle cells, thereby attenuating PDE4D activity and increasing cAMP accumulation. This PDK1/Akt/PDE4D axis was identified as a novel mechanism controlling airway smooth muscle relaxation.\",\n      \"method\": \"Chemical proteomics (drug-protein capture), molecular dynamics simulation, in vitro PDK1 kinase assay, PDE4D phosphorylation Western blot, cAMP measurement, tracheal smooth muscle contractility assay\",\n      \"journal\": \"Allergy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chemical proteomics identification with kinase assay and functional smooth muscle readout, single lab\",\n      \"pmids\": [\"26335809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"PDE4D overexpression in tamoxifen-resistant ER+ breast cancer cells suppresses cAMP/ER-stress/p38-JNK signaling and apoptosis. Inhibition of PDE4D (siRNA or pharmacological inhibitors) restores tamoxifen sensitivity by reactivating cAMP-mediated unfolded protein response/ER stress pathway and p38/JNK-dependent apoptosis.\",\n      \"method\": \"siRNA knockdown, pharmacological inhibitors (dipyridamole, GEBR-7b), cAMP measurement, UPR/p38/JNK pathway immunoblotting, apoptosis assays, in vivo xenograft tumor growth\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA and pharmacological inhibition with defined downstream pathway (cAMP→UPR→p38/JNK), in vivo confirmation; single lab\",\n      \"pmids\": [\"29386221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"PDE4D expression and activity are approximately 2-fold elevated in asthmatic airway smooth muscle cells, accounting for reduced beta2-agonist-induced cAMP accumulation; specific PDE4 inhibition normalizes cAMP production and reduces asthmatic ASM proliferation but not non-asthmatic ASM proliferation.\",\n      \"method\": \"Primary cultured ASM from asthmatic vs. non-asthmatic subjects, cAMP accumulation assay with/without PDE inhibitors, PDE4D protein quantification, proliferation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — primary human cells with pharmacological rescue and functional proliferation readout, moderate sample size; single lab\",\n      \"pmids\": [\"21611147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PDE4D protein localizes to dendrites associated with microtubules, mitochondria, and smooth endoplasmic reticulum, with postsynaptic labeling in dendritic spines near glutamatergic synapses and in perisynaptic astroglial leaflets in macaque dlPFC layer III pyramidal cell circuits, as determined by immunoelectron microscopy.\",\n      \"method\": \"Laser-capture microdissection transcriptomics, high-resolution immunoelectron microscopy in rhesus macaque dlPFC\",\n      \"journal\": \"Frontiers in neuroanatomy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ultrastructural localization by immunoelectron microscopy with transcriptomic support, but no direct functional consequence established in same study\",\n      \"pmids\": [\"33328902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A co-crystal structure of PDE4B (catalytic domain) with triazine inhibitors shows the compounds interact with both the catalytic pocket and the C-terminal regulatory helix (CR3), locking the enzyme in an inactive 'closed' conformation; structure-activity relationships define CR3 contacts as the basis for PDE4B vs. PDE4D subtype selectivity.\",\n      \"method\": \"X-ray co-crystallography of PDE4B–triazine complex, structure-activity relationship analysis of selective inhibitors\",\n      \"journal\": \"Bioorganic & medicinal chemistry letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — crystal structure with SAR but selectivity mechanism for PDE4D inferred from PDE4B structure; direct PDE4D structure not determined\",\n      \"pmids\": [\"24998378\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In the PDE4D/cAMP/IL-23 axis in lung adenocarcinoma, PDE4D activity in tumor cells suppresses cAMP, reducing IL-23 production; PDE4D inhibition elevates cAMP and IL-23, which activates CTL NF-κB signaling to induce an IL-9 autocrine loop, enhancing CTL effector function and immunotherapy efficacy.\",\n      \"method\": \"Co-culture system (LUAD cells + tumor-specific CD8+ T cells), fluorescent multiplex IHC, transcriptome sequencing, functional validation with PDE4D manipulation and IL-23/IL-9/NF-κB pathway assays, in vivo mouse xenograft\",\n      \"journal\": \"Cancer letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multi-step pathway defined by functional assays in co-culture and in vivo; single lab\",\n      \"pmids\": [\"37196909\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PDE4D is a cAMP-specific phosphodiesterase whose multiple splice variants (PDE4D1–9) are differentially targeted to distinct subcellular compartments via their unique N-terminal regions; catalytic activity is subject to complex post-translational regulation including PKA-mediated activation (providing negative feedback on cAMP signals), ERK2 phosphorylation that either inhibits (long isoforms via UCR1/UCR2) or activates (short isoforms via UCR2 alone) the enzyme, CaMKII-mediated activation, and integrin α5-recruited PP2A-B55α-mediated dephosphorylation of the inhibitory Ser651 site in PDE4D5; structurally, allosteric modulators exploit a regulatory domain that closes over the active site; in tissues PDE4D functions as the dominant terminator of beta2AR-stimulated cAMP in fibroblasts and heart, controls muscarinic cholinergic airway contraction, governs GLP-1 secretion and beta-cell function, mediates antidepressant and pro-cognitive effects of cAMP elevation, and promotes inflammation in atherosclerotic endothelium by suppressing cAMP downstream of fibronectin/integrin α5; loss-of-function mutations cause acrodysostosis by impairing cAMP-PKA signaling in bone, while gain-of-function or overexpression drives pathological remodeling in heart, liver, and cancer.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PDE4D is a cAMP-specific phosphodiesterase that serves as a dominant terminator of cAMP signaling across diverse tissues, with its multiple alternatively spliced variants (PDE4D1\\u20137) differentially compartmentalized through unique N-terminal regions that confer cytosolic, particulate, or nuclear targeting [#2, #19]. Catalytic output is governed allosterically by a regulatory domain (UCR2/CR3) that closes over the active site, the conformation small-molecule modulators exploit to achieve partial inhibition [#0]. The enzyme is integrated into multiple feedback and signaling networks: PKA phosphorylates and activates long PDE4D isoforms to terminate cAMP signals [#3, #10], ERK2 phosphorylation at Ser579 inhibits long isoforms (via UCR1/UCR2) but activates short isoforms bearing UCR2 alone [#1], and CaMKII activates PDE4D in cardiomyocytes to constrain beta-adrenergic cAMP [#15]. Conversely, integrin \\u03b15 binds PDE4D5 on fibronectin matrix and recruits PP2A via its B55\\u03b1 subunit to dephosphorylate the inhibitory Ser651 site, activating the enzyme, suppressing cAMP, and driving endothelial inflammation in atherosclerosis [#13, #14]. Through these compartmentalized circuits PDE4D controls beta2-adrenergic cAMP and CREB-dependent transcription in fibroblasts [#10, #11], muscarinic cholinergic airway contraction [#8, #9], and GLP-1 secretion and beta-cell function [#20, #26]. Loss-of-function missense mutations in PDE4D cause acrodysostosis, a skeletal dysplasia with brachydactyly and intellectual disability arising from disrupted cAMP-PKA signaling in bone and CNS [#23, #22], whereas elevated PDE4D drives pathological remodeling in heart, liver, and cancer, in part through PKA-dependent control of YAP phosphorylation and degradation [#25, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that PDE4D's multiple splice variants are not redundant but are addressed to distinct subcellular compartments by their unique N-termini, explaining how one gene tunes cAMP in different locations.\",\n      \"evidence\": \"Transient expression in COS-7 cells with subcellular fractionation and rolipram IC50 determination across five isoforms\",\n      \"pmids\": [\"9371713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the molecular anchors binding each particulate isoform\", \"Functional consequence of compartmentalization for cAMP gradients not measured\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Showed that isoform targeting involves distinct anchoring mechanisms and that hormone-driven PKA phosphorylation activates PDE4D3, linking localization to regulated catalytic control.\",\n      \"evidence\": \"Subcellular fractionation, differential detergent extraction, immunofluorescence and TSH stimulation in FRTL-5 thyroid cells\",\n      \"pmids\": [\"9677395\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the ionic-detergent-resistant anchor for PDE4D4 not determined\", \"PKA phosphosites not mapped in this study\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved how a single gene produces both ERK2-inhibited and ERK2-activated isoenzymes by mapping ERK2 docking sites and the role of the UCR1/UCR2 module, establishing isoform-dependent kinase regulation.\",\n      \"evidence\": \"Docking-site mutagenesis, reciprocal Co-IP, in vitro ERK2 kinase assay and cellular cAMP readouts in COS cells\",\n      \"pmids\": [\"10828059\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological contexts where ERK2 inhibition versus activation dominates not defined\", \"Crosstalk with PKA phosphorylation on the same isoform not resolved\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic ablation demonstrated PDE4D is required in vivo for gonadotropin signaling, growth, and fertility, moving the gene from a biochemical entity to an essential physiological cAMP regulator.\",\n      \"evidence\": \"PDE4D-/- knockout mouse with PDE4 activity assays and ovulation/fertility phenotyping\",\n      \"pmids\": [\"10518565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which isoforms mediate the granulosa cell phenotype not dissected\", \"Cell-autonomous versus systemic contributions not separated\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Defined PDE4D as essential for muscarinic cholinergic airway contraction and traced the knockout phenotype to elevated cAMP driving prostanoid accumulation, providing a mechanistic pathway for airway tone.\",\n      \"evidence\": \"PDE4D-/- trachea contractility, cAMP and prostanoid measurements with prostanoid-synthesis-blockade rescue, in vivo airway assays\",\n      \"pmids\": [\"14519662\", \"10841571\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific cell type generating PGE2 not pinpointed\", \"Isoform responsible for airway smooth muscle cAMP control not identified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Crystal structures of the catalytic domain with rolipram explained inhibitor selectivity at the residue level, including a key role for Gln369 conformation, informing selective inhibitor design.\",\n      \"evidence\": \"X-ray crystallography of PDE4D2 catalytic domain\\u2013rolipram complexes with comparison to PDE5/PDE7\",\n      \"pmids\": [\"12834813\", \"12842049\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic domain alone does not capture regulatory-domain allostery\", \"Isoform-specific kinetic differences not structurally explained\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Co-crystal structures revealed the regulatory UCR2/CR3 domain closes over the active site, establishing the structural basis of allosteric, partial inhibition exploitable for safer therapeutics.\",\n      \"evidence\": \"Seven X-ray co-crystal structures with mutagenesis, enzyme kinetics, cellular cAMP assays and in vivo emesis models\",\n      \"pmids\": [\"20037581\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dynamics of the open/closed equilibrium in full-length enzyme not captured\", \"How post-translational modifications shift this equilibrium not resolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Isoform-selective knockouts with spatially resolved cAMP sensors showed PDE4D and PDE4B operate in distinct subcellular cAMP pools, with PDE4D uniquely controlling bulk-cytosol cAMP and CREB transcription, establishing compartmentalized signaling.\",\n      \"evidence\": \"PDE4B and PDE4D knockout MEFs with FRET cAMP sensors, CREB reporters and isoproterenol stimulation; PKA feedback dissected with H89/PKI\",\n      \"pmids\": [\"21288894\", \"18508768\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular determinants restricting each enzyme to its pool not defined\", \"How distinct pools couple to specific downstream effectors not mapped\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified a defined signaling complex of PDE4D with EPAC1 at VE-cadherin junctions that controls endothelial barrier function, linking PDE4D scaffolding to vascular permeability.\",\n      \"evidence\": \"Reciprocal Co-IP, fractionation, cell-permeable EPAC1 peptide disruption and permeability assays in human arterial endothelial cells\",\n      \"pmids\": [\"20732872\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PDE4D isoform within the complex not specified\", \"Whether catalytic activity or scaffolding drives the permeability effect not separated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that integrin \\u03b15 directly binds PDE4D5 and recruits PP2A-B55\\u03b1 to dephosphorylate inhibitory Ser651, activating the enzyme and driving atherosclerotic endothelial inflammation, linking matrix sensing to cAMP suppression.\",\n      \"evidence\": \"Integrin \\u03b15/\\u03b12 chimera knock-in mice, siRNA, Co-IP, Ser651 phospho-specific antibodies, cAMP measurement and in vivo inflammation assays; B55\\u03b1 confirmed by proteomics and in vitro phosphatase assay\",\n      \"pmids\": [\"27595237\", \"31408443\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other integrins use this PDE4D5 axis not tested\", \"Stoichiometry and assembly order of the integrin-PDE4D5-PP2A complex not resolved\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Extended the kinase regulation network by showing CaMKII activates PDE4D in cardiomyocytes, integrating Ca2+ and cAMP signaling as a negative feedback constraining beta-adrenergic cAMP.\",\n      \"evidence\": \"CaMKII inhibitor pharmacology, PDE4D activity assays and cAMP measurements in cardiomyocytes\",\n      \"pmids\": [\"25646485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CaMKII phosphosite on PDE4D not mapped\", \"Single-lab pharmacological approach without genetic confirmation\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Human genetics established that heterozygous PDE4D loss-of-function mutations cause acrodysostosis without hormone resistance, defining a Mendelian disease arising from disrupted cAMP homeostasis in bone and CNS.\",\n      \"evidence\": \"Exome/Sanger sequencing of patients with zebrafish overexpression and morpholino knockdown producing mirror skeletal phenotypes; KO rat radiographic phenotyping and HEK293 catalytic assays\",\n      \"pmids\": [\"24203977\", \"22464252\", \"22464250\", \"25064455\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Paradoxical low cAMP in patient cells from PDE4A/PDE4B compensation complicates genotype-phenotype interpretation\", \"Affected bone/CNS cell types and developmental windows not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established PDE4D as a driver of pathological remodeling in heart, liver, and cancer, acting through PKA-controlled YAP phosphorylation/degradation and CREB-SIRT1-mitophagy axes, defining therapeutic rationale for PDE4D inhibition.\",\n      \"evidence\": \"Gain/loss-of-function mouse models (cardiac haploinsufficiency, hepatic and AAV9 overexpression), Co-IP, YAP-S127A rescue, roflumilast treatment and pathway readouts across HCC, NAFLD/hypertension and heart failure models\",\n      \"pmids\": [\"35597479\", \"34826603\", \"40015131\", \"29386221\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether the same isoform mediates effects across organs not resolved\", \"Single-lab models for each disease context without independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the full repertoire of PDE4D isoforms, their distinct compartmental anchors, and the competing kinase/phosphatase inputs are integrated to shape tissue-specific cAMP microdomains in vivo.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking specific isoforms to specific cAMP pools across tissues\", \"Anchor proteins for most particulate isoforms remain unidentified\", \"In vivo dynamics of opposing PKA/ERK2/CaMKII/PP2A regulation not measured directly\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 2, 6, 18]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3, 19]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [3, 11, 12]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [3, 31]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [10, 11, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [13, 14, 23, 25, 27]}\n    ],\n    \"complexes\": [\n      \"PDE4D5-integrin \\u03b15-PP2A(B55\\u03b1)\",\n      \"EPAC1-PDE4D-VE-cadherin\",\n      \"PDE4D5-RACK1-FAK\"\n    ],\n    \"partners\": [\n      \"EPAC1\",\n      \"ITGA5\",\n      \"PPP2R2A\",\n      \"YAP1\",\n      \"HSPB6\",\n      \"RACK1\",\n      \"PTK2\",\n      \"MAPK1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}